Evidence map›Paper›PMID 37597071›Full record

ArticleJournal of neurology2023

Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy.

Shemonti Hasan, Onilia Zorio, B Mark Keegan, Brian G Weinshenker, Eoin P Flanagan, W Oliver Tobin, Orhun H Kantarci, Michel Toledano, Sean J Pittock, Sebastian Lopez-Chiriboga and 2 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shemonti HasanDepartment of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
Onilia ZorioDepartment of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA.
B Mark KeeganDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Brian G WeinshenkerDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Eoin P FlanaganDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
W Oliver TobinDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Orhun H KantarciDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Michel ToledanoDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Sean J PittockDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Sebastian Lopez-ChiribogaDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Anastasia ZekeridouDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Cristina Valencia-SanchezDepartment of Neurology, Mayo Clinic Arizona, 13400 East Shea Blvd, Scottsdale, AZ, 85259, USA. valenciasanchez.cristina@mayo.edu.ORCID http://orcid.org/0000-0003-0116-8035

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Demyelinating DiseasesNeoplasmsHumansImmune Checkpoint InhibitorsImmune Checkpoint Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.